Actively Recruiting
High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
Led by Zhejiang University · Updated on 2026-05-04
600
Participants Needed
3
Research Sites
49 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypoxia represents the most frequent adverse event during propofol-sedated gastrointestinal endoscopy. The STOP-BANG questionnaire serves as a widely adopted, straightforward tool for screening obstructive sleep apnea (OSA) risk, with a score ≥5 identifying high-risk OSA patients who are particularly susceptible to hypoxia under sedation. Although preliminary research from our team suggests that High-Flow Nasal Cannula (HFNC) may lower the incidence of hypoxemia, evidence remains limited and inconsistent in studies specifically targeting high-risk OSA populations. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxia during sedated gastrointestinal endoscopy in patients identified as high-risk for OSA.
CONDITIONS
Official Title
High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- STOP-Bang score 5 or higher
- Scheduled for sedated gastrointestinal endoscopy (gastroscopy, colonoscopy, or combined gastroscopy and colonoscopy)
- Procedure expected to last no more than 45 minutes
- Signed informed consent form
You will not qualify if you...
- Coagulation disorders or bleeding tendency, including risk of oral or nasal bleeding and mucosal injury
- Active upper respiratory tract infection or fever with core temperature above 37.5C
- Chronic obstructive pulmonary disease or other pulmonary diseases requiring oxygen therapy, or preoperative oxygen saturation (SpO2) 92% or less on room air
- Severe organ dysfunction including cardiac insufficiency with less than 4 METs, severe renal insufficiency requiring dialysis, severe hepatic insufficiency, increased intracranial pressure, or ASA physical status class IV or higher
- Confirmed pregnancy or currently breastfeeding
- Known allergy to sedatives such as propofol or to medical adhesives
- Multiple traumatic injuries
- Current participation in another clinical trial
- Other conditions judged unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
2
The First Hospital Of Jiaxing
Jiaxing, Zhejiang, China, 314000
Actively Recruiting
3
Quzhou People's Hospital
Quzhou, Zhejiang, China, 324000
Actively Recruiting
Research Team
D
Diansan Su, Chief Physician
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here